Aptus Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
Other funds holding OCUL
SR
Aptus Capital Advisors's OCUL Position: Q3 2026 in Review
Aptus Capital Advisors increased its Ocular Therapeutix (OCUL) stake by 2.9% in Q3 2026, buying an estimated $178K and bringing the position to 656,908 shares worth $5.04M. The position accounts for 0.03% of the portfolio, ranked #387.
Aptus Capital Advisors first reported a position in OCUL in Q2 2024 and has held it in 10 quarters since. The position peaked at $6.27M in Q2 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.
- Aptus Capital Advisors held 656,908 shares of Ocular Therapeutix worth $5.04M as of Q3 2026.
- Aptus Capital Advisors bought 18,217 Ocular Therapeutix shares in Q3 2026, an estimated $178K.
- Ocular Therapeutix made up 0.03% of Aptus Capital Advisors's portfolio in Q3 2026, its #387 holding.
- Aptus Capital Advisors first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 10 quarters since.
- Aptus Capital Advisors's Ocular Therapeutix position peaked at $6.27M in Q2 2026.
- 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.
Based on Aptus Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.